Instead of waiting to use Tarceva when all else was failing, he decided to use it as part of a tailor-made drug cocktail for his patient based on the information from the diagnostic he developed while staying within the bounds of the FDA. The patient fared better than most of the patients Lester sees.
Itâ€™s not a cure, but the results of Lesterâ€™s experimentâ€”and others like itâ€”are being shared with academic researchers and drug companies to accelerate the development of cancer drugs tailored to variations of growth factors causing lung cancer. Patients like Lesterâ€™s would receive tests that look for biomarkersâ€”biochemical indicators of a diseaseâ€”to see which drug would work best with fewest side effects. Such collaboration could bring about a new generation of cancer-killing treatments in years.
For more check out the Journal of Life Sciences at:
And that will explain the title.